Howard Chang’s group recently showed that targeted CRISPR interference at the PVT1 promoter enhanced breast cancer cell competition and growth in vivo due to the competition between PVT1 and MYC for engagement with four intragenic enhancers in the PVT1 locus (60). This evidence concerns the gene PVT1 and breast carcinoma.